Balentine LLC’s abrdn Life Sciences Investors HQL Stock Holding History

Balentine LLC’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,933	Closed	-$134K	–	769
2019 Q2	$134K	Buy	7,933 +317	+4%	+$5.22K	0.01%	65
2019 Q1	$130K	Buy	7,616 +212	+3%	+$3.66K	0.01%	75
2018 Q4	$112K	Buy	+7,404	New	+$130K	0.01%	80

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Balentine LLC's HQL Position: Q3 2019 in Review

Balentine LLC sold out of abrdn Life Sciences Investors (HQL) in Q3 2019, closing a stake of 7,933 shares — an estimated $134K sold.

Balentine LLC first reported a position in HQL in Q4 2018 and held it in 3 quarters. The position peaked at $134K in Q2 2019. 61 funds tracked by Wall St. Rank hold HQL as of Q3 2019.

Balentine LLC reported no remaining abrdn Life Sciences Investors position as of Q3 2019 after selling out during the quarter.
Balentine LLC sold 7,933 abrdn Life Sciences Investors shares in Q3 2019, an estimated $134K.
Balentine LLC first reported a position in abrdn Life Sciences Investors in Q4 2018 and held it in 3 quarters.
Balentine LLC's abrdn Life Sciences Investors position peaked at $134K in Q2 2019.
61 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2019.

Based on Balentine LLC's 13F filing for Q3 2019, filed 15 Nov 2019.